Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 327

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 327
---
 regulatory approval for a new supplier could result in additional
costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Our dependence
on single-source suppliers exposes us to numerous risks, including the following: our suppliers may cease or reduce production or deliveries,
raise prices or renegotiate terms; our suppliers may become insolvent or cease trading; we may be unable to locate a suitable replacement
supplier on acceptable terms or on a timely basis, or at all; and delays caused by supply issues may harm our reputation, frustrate our
customers and cause them to turn to our competitors for future needs.

Risks
Relating to the Ownership of Our Common Stock

Future
sales of our common stock, or the perception that future sales may occur, may cause the market price of our common stock to decline,
even if our business is doing well.

Sales
of substantial amounts of our common stock in the public market after our IPO, or the perception that these sales may occur, could materially
and adversely affect the price of our common stock and could impair our ability to raise capital through the sale of additional equity
securities. Those shares of common stock sold in our IPO will be freely tradable, without restriction, in the public market, except for
any shares sold to our affiliates.

After
the date of the IPO, when 1,000,000 shares of common stock became publicly tradable, approximately 23,891,902 additional shares of common
stock were subject to “lock-up” agreements entered into in connection with the IPO, are or will become eligible to be sold
in the public market by existing stockholders by February 9, 2025 as a result of Rule 144 of the Securities Act, subject to volume and
other limitations imposed under the federal securities laws. Furthermore, additional shares of our common stock may be publicly tradable
as a result of exercises of stock options and restricted stock units (RSUs) under the 2023 Omnibus Incentive Plan. Sales of substantial
amounts of our common stock in the public market after the completion of the IPO, or the perception that such sales could occur, could
adversely affect the market price of our common stock and could materially impair our ability to raise capital through offerings of our
common stock.

Because
of the speculative nature of an investment in our company, you may lose your entire investment.

An
investment in our securities carries a high degree of risk and should be considered as a speculative